Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

British Journal of Cancer

Volumn 81, Issue 8, 1999, Pages 1294-1303

  O'Neill, C F ^a   Koberle, B ^b   Masters, J R W ^b   Kelland, L R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Cisplatin; Gene specific repair; JM216

Indexed keywords

CISPLATIN; DNA FRAGMENT; PROPIDIUM IODIDE; PROTEIN P53; SATRAPLATIN;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL LABELING; CELL LEVEL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG RESISTANCE; FLUORESCENCE MICROSCOPY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; ONCOGENE N RAS; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0032713064     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6694381     Document Type: Article

References (43)

1. Burton K (1956) A study of the condition and mechanism of the diphenylamine reaction for the coloroictric estimation of deoxyribonucleic acid. Biochem J 62: 315-323
2. Fogh J, Wright WC and Lovelass JD (1977) Absence of HeLa cell contamination in 169 cell lines transformed in vitro. J Natl Cancer Inst 58: 209-214
3. Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Barnard CFJ, Harrap KR, Goddard PM, Kelland LR and Morgan SE (1991) Synthesis and reactions of a new class of orally active Pt(IV) antitumour complexes. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Howell SB (ed), pp. 93-100. Plenum: New York
4. Grimaldi KA, Bingham JP, Souhami RL and Hartly JA (1994) DNA damage by anti cancer agents: mapping in cells at the subgene level with quantitative PCR. Analyst Biochem 222: 236-242
5. Hainaut P (1995) The tumour suppresser protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 7: 76-82
6. Harrap KR, Murrer BA, Giandomenico CM, Morgan SE, Kelland LR, Jones M, Goddard PM and Schurig J (1991) Ammine/amine platinum IV platinum dicarboxylates a novel class of complexes which circumvent intrinsic cisplatin resistance. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Howell SB (ed). pp. 93-100. Plenum: New York
7. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP and Harrap KR (1989) Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527-534
8. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF and Hamilton TC (1994) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47: 689-697
9. Kastan MB, Omyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in cellular response to DNA damage. Cancer Res 51: 6304-6311
10. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P and Harrap KR (1992a) Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complexes exhibiting selective cytotoxicity to intrinsic cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 52: 822-828
11. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA and Harrap KR (1992b) Mechanism-related circumvention of acquired cisdiamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 52: 3857-3864
12. Kelland LR, Abel G, Mckeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA and Harrap KR (1993) Preclinical antitumour evaluation of bis acetato-ammine-dichloro-cyclohexylamine platinum (TV): an orally active platinum drug. Cancer Res 53: 2581-2586
13. Kirby KS and Cook EA (1967) Isolation of deoxyribonucleic acid from mammalian tissue. Biochem J 104: 254-257
14. Koberle B, Payne J, Grimaldi KA, Hartley JA and Masters JRW (1996) DNA repair in cisplatin sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. J Biochem Pharmacol 52: 1729-1734
15. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR and Masters JRW (1997) DNA repair capacity and cisplatin sensitivity of human testis tumour lines. Int J Cancer 70: 551-555
16. Lowe SW, Ruley HE, Jacks T and Housman DE (1993) P53 dependent apoptosis modulates the cytotoxicity of anti cancer agents. Cell 74: 957-967
17. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Ficher DE, Housman DE and Jacks T (1994) P53 status and the efficacy of cancer therapy in vivo. Science (Washington DC) 266: 807-810
18. Lowry OH, Rosenbrough MT, Farr AL and Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265-269
19. McKeage MJ, Mistry P, Ward J, Boxall FE, Lob S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer BA, Santabarbara P, Harrap KR and Judson IR (1995) Phase I and pharmacological study of an oral platinum complex (JM216): dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36: 451-458
20. McLlwrath AJ, Vasye PA, Ross GM and Brown B (1994) Cell cycle arrests and radiosensitivity of human tumour cell lines. Dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718-3722
21. Mellish KJ, Kelland LR and Harrap KR (1993) In vitro platinum drug sensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68: 240-250
22. Mellish KJ and Kelland LR (1994) Mechanisms of acquired resistance to the orally active platinum-based anticancer drug JM216/bis acetato-ammine dichloro cyclohexylamine platinum (IV) in two human ovarian carcinoma cell lines. Cancer Res 54: 6194-6200
23. Mistry P, Kelland LR, Abel G, Sidhar S and Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215-220
24. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR and Sikorska M (1993) Apoptotic death in epithelial cells, cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684
25. O'Neill CE, Orr RM, Kelland LR and Harrap KR (1995) Comparison of platinum binding to DNA and removal of total platinum adducts and inter-strand cross-links in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Cellular Pharmacol 2: 1-7
26. O'Neill CF, Ormerod MG, Robertson D, Titley JC, Cumber-Walsweer Y and Kelland LR (1996) Apoptotic and non apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine) dihydroxodichloroplatinum(IV) complex. Br J Cancer 74: 1073-1045
27. Ormerod MG, Payne AWR and Watson JV (1987) Improved programme for the analysis of DNA histograms. Cytometry 8: 637-641
28. Ormerod MG, O'Neill CF, Robertson D and Harrap KR (1994a) Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res 211: 231-237
29. Ormerod MG, Orr RM and Peacock JH (1994b) The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer 69: 93-100
30. Ormerod M, O'Neill C, Robertson D, Kelland LR and Harrap KR (1996) Cis-diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37: 463-471
31. Perego P, Giarola M, Righetti SC. Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of the p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562
32. Pestell KE, Medlow CJ, Titley JC, Kelland LR and Watton MI (1998) Characterisation of the P53 status, Bcl-2 expression and radiation and platinum drug sensitivity of a panel of human ovary cancer cell lines. Int J Cancer 77: 913-918
33. Petersen LN, Mamenta EL, Stevenser T, Chaney SG and Bohr VA (1996) Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines and studies on carrier ligand specificity. Carcinogenesis 17: 2597-2602
34. Poon GK, Raynaud FI, Mistry P, Odell DE, Kelland LR, Harrap KR, Barnard CFJ and Murrer BA (1995) Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionisation-mass spectrometry. J Chromatogr 712: 61-66
35. Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CFJ, Murrer BA and Harrap KR (1996a) Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38: 155-162
36. Raynaud FI, Odell DE and Kelland LR (1996b) Intracellular metabolism of the orally active platinum drug JM216: influences of glutathione levels. Br J Cancer 73:
37. Sorenson CM and Eastman A (1988) Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48: 6703-6707
38. Twentyman PR, Wright KA, Mistry PA, Kelland LR and Murrer BA (1992) Sensitivity to novel platinum compounds in panels of human lung cancer cell lines with acquired and inherent resistance of cisplatin. Cancer Res 52: 5674-5680
39. Vaisman A, Varchenko M, Said I and Chaney SG (1997) Cell cycle changes associated with the formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27: 54-64
40. Winters ZE, Ongkeko WM, Harris AL and Norbury CJ (1998) p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation induced G2 arrest in human cells. Oncogene 17: 673-684
41. Yaginuma Y and Westphal H (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 52: 4196-4199
42. Zaffaroni N, Silvestrini R, Orlandi L, Bearzatto A. Gornati D and Villa R (1998) The induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin, sensitive and resistant human ovarian cancer cells. Br J Cancer 77: 1378-1385
43. Zhen W, Link CJ, O'connor PM, Reed E, Parker R, Howell SB and Bohr VA (1992) Increased gene-specific repair of cisplatin intrastrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689-3698